What patients pay for Botox, and what is known about raising prices or retiring a service

Who this is for

This is for the physician or medical professional who owns an aesthetic practice, and/or the operations lead who sets the practice's prices and decides which services stay on the menu.

Most published pricing advice for med spas is opinion from consultants and the companies that sell practice software. It tends to be confident, and it seldom shows a measurement.

The measured numbers come from patients' own reports on RealSelf, Guidepoint Qsight's practice transaction data, AbbVie's list price for Botox Cosmetic, the American Society of Plastic Surgeons' fee survey, the Bureau of Labor Statistics, two peer-reviewed journals, Zenoti's customer data, and a Federal Reserve brief on supermarket customers.

Each price below names its layer (what the practice pays for the product, the physician's fee, or the patient's total bill) and who reported it.

We sell growth strategy and digital marketing. We sell no pricing or membership product, so neither choice changes what we earn.

What do patients pay for Botox, and who reports each price?

The patient-side numbers held level or rose. The one series that fell is a survey of physicians' fees, and its sample changed between the two years it compares.

RealSelf, a site where patients review cosmetic treatments, carries the patient's own report of the total bill. The version of its Botox cost page updated April 6, 2022 said Botox costs $550 on average, according to 18,233 reviews from RealSelf members.¹ The version updated June 9, 2023 said $553, according to 7,827 patient reviews.²

The 2023 page says prices on the higher end typically cover multiple areas, larger muscle groups, or Botox combined with another treatment such as filler.² The pool of reviews behind the two averages differs in size, so we treat the $3 rise as about level.

Guidepoint Qsight, a firm that measures practice sales from patient transaction data it does not publish, reported in October 2026 that men's average neurotoxin spend per transaction reached $529 in the third quarter of 2026 to date. That is the highest figure it has recorded in nearly five years of tracking, and Qsight attributes it to men receiving 10-15% more units per visit.³

The Qsight data point comes from practice records, covers men only, and is three years later than the RealSelf averages, so the two sit on different bases.

One layer down is the practice's cost of goods. AbbVie, which makes Botox Cosmetic, listed a 100-unit vial at $656.00 in a list-price disclosure current as of February 2024. The same document says this list price, the wholesale acquisition cost, may not reflect the price paid by patients or insurers.⁴

The figure that fell comes from the American Society of Plastic Surgeons (ASPS). In its survey, the average surgeon or physician fee for a neuromodulator injection fell 18% ($528 in 2022, $435 in 2023). The fee for hyaluronic acid filler fell 10% ($794 in 2022, $715 in 2023), and for non-hyaluronic filler 13% ($1,039 in 2022, $901 in 2023).^5,6

ASPS calls this the "average surgeon/physician fee." Its 2022 table says the fees are averages only and "do not include anesthesia, operating room facilities or other related expenses." Neither year's table says whether the fee includes the toxin or filler itself, or whether it is charged per visit or per treatment area.^5,6

The survey's sample changed between the two years. For 2022, ASPS sent its questionnaire to more than 24,600 board-certified physicians, combined the answers with data from two affiliated companies, CosmetAssure and PatientNow, and kept 1,151 physicians in the final sample.⁷

For 2023, ASPS used CosmetAssure only. It sent the questionnaire to more than 12,000 plastic surgeons, dermatologists and otolaryngologists, and drew on 678 plastic surgeons from CosmetAssure's data, 148 dermatologists and otolaryngologists, and 830 responses from ASPS members.⁸ ASPS still printed the two years side by side in its 2023 table.⁶

A change between two years of a survey counts as a trend when the same kind of people answered the same way. Here they did not, and the 2023 fee cannot show on its own whether physicians charged less or a different group answered.

National averages also hide local spread. A 2023 study in Aesthetic Surgery Journal, a peer-reviewed journal, found 66 practices that posted cosmetic surgery prices online. Their posted prices ran significantly higher than national averages for most surgical procedures, and prices differed by region for most procedures.⁹

How fast are prices rising across the economy, and does that data cover aesthetics?

Faster in the spring of 2026 than in the winter, and the government data has no series for aesthetic procedures.

The Bureau of Labor Statistics put the all-items index up 2.4% over the year to February 2026 and 4.2% over the year to May. Leaving out food and energy, the rise was 2.5% and 2.9%.^10,11

Medical care services rose 4.1% and 3.6% over the same two periods. Physicians' services rose 2.1% and 2.9%. Personal care services, the index that covers haircuts and similar services, rose 4.9% and 3.6%.^10,11

The Bureau's fact sheet describes physicians' services as care billed by physicians in private practice, including office and clinic visits. It does not mention cosmetic or elective procedures.¹² Neither release lists a series for neurotoxin or filler, and the nearest row is cosmetics sold as products.^10,11

A practice that lifts every price by the inflation rate is matching the wider economy. Those indexes say nothing about demand for aesthetics.

Which services and which patients are bringing in more spending?

On the data available, neurotoxin and the patients who spend more per visit. Filler spending and the share of new patients both fell.

Qsight estimated U.S. neurotoxin spending at $6.4 billion in 2024. That was 31% of non-surgical aesthetic spending and 8% more than in 2023.¹³

For the first quarter of 2026, Qsight put neurotoxin spending at $1.7 billion, up 4% on the year, and dermal filler at $840 million, down 5%.¹⁴

Qsight also found that about half of filler visits include a neurotoxin, while about 13% of neurotoxin visits include filler, down from around 21% in 2017. Qsight describes neurotoxin as a primary entry point.¹³ We infer that a change to the filler price lands mostly on patients who came in for neurotoxin.

Procedure counts kept rising. A 2026 blog post from Cosmetic Injectables, quoting the ASPS 2024 statistics release, lists 9,883,711 neuromodulator injections, 5,331,426 hyaluronic acid filler procedures and 932,861 non-hyaluronic filler procedures in 2024, within 28,243,407 minimally invasive procedures, up 1.5% on 2023.¹⁵

Zenoti, a company that sells practice software, published 2025 benchmarks from medspas on its platform. The average ticket at the 90th-percentile location rose 7% ($454 to $484), and Zenoti describes it as trending back toward the $500 level it saw in 2023. The 75th-percentile location averaged $346 a ticket and the median location $216, under half the top data point.¹⁶

A ticket is the patient's total bill for a visit and can hold several procedures plus retail. The ASPS fee is a per-procedure physician fee, so the two measure different layers.

Price sensitivity also differs by patient. A 2026 peer-reviewed study in the Journal of Plastic, Reconstructive and Aesthetic Surgery asked 2,335 respondents what they would pay for five cosmetic surgeries. Willingness to pay was higher among people aged 18 to 24, people earning over $150,000, and people who had used Botox or filler before.¹⁷

That study measured stated answers about surgery. Our reading is that a single increase across the menu treats the median patient and the top-decile patient as one group, and both data sets show them behaving differently.

Fewer of the patients are new. In Qsight's data, first-time patients fell to 41% of the total in the twelve months to March 2026, from 55% in 2021, and retention edged up from 51% to 53% over the same years.¹⁴

Zenoti's 2026 trends page reports new client visits at medspas down 11% and existing client visits down 2%, with membership sales up 13% on the year.¹⁸ Its 2025 benchmarks show the cancellation rate improving from 16% to 14%.¹⁶

Zenoti's pricing guidance puts a med spa membership at $149 to $249 a month. That range is the company's advice. Zenoti sells booking and membership software, and it publishes no data point on whether members spend more over a year.¹⁹

Our reading is that with fewer new patients arriving, each patient who leaves after a price change is harder to replace.

What happens to patients after a price rise or a dropped service?

In aesthetics, almost nothing has been measured. The nearest measured result comes from a supermarket chain.

A 2023 Federal Reserve Bank of Richmond brief used loyalty-card records from a major U.S. supermarket chain. Its model estimated that a 1% price change raised a store's yearly customer turnover from 14% to 21%.²⁰

Our reading is that a price rise loses some customers, and the loss can be large for the size of the change. The brief tests this on grocery shoppers and says nothing about a medical practice.

The 2026 willingness-to-pay study gives a second hint: past injectable patients said they would pay more for surgery.¹⁷ We take that to mean loyal, high-spend patients may absorb an increase better than new ones. It is a hint from stated answers, and no study has measured it for injectables.

Neither aesthetic study measures bookings before and after a price increase.^9,17

On retiring a service, the spending and cross-purchasing data are the firmest ground. Two questions sort a service: do patients book it on its own, and is spending on it growing or shrinking?

For the two biggest injectables, Qsight's data answers both. Neurotoxin draws patients by itself and its spending is growing. Filler is more often added to a neurotoxin visit, and its spending fell 5% in the first quarter of 2026.^13,14

Our reading is that a service that mostly rides along with another is a candidate to reprice or repackage before it is cut. A patient who booked a service for years may also take its removal as the practice moving away from them. No study measures how aesthetic patients respond to a dropped service.

Compare a price only with the same layer elsewhere: a patient's bill with a patient's bill, a vial with a vial.

Treat the high-spend patient and the median patient as two separate pricing questions.

Before cutting a service, look at whether patients book it alone or only alongside neurotoxin.

Hold any consultant's or vendor's pricing rule, and any change between two years of a survey, as opinion until someone shows the measurement and the method, and weigh it against the practice's own booking records.

About this review

We read RealSelf's Botox cost page in Internet Archive copies from May 2022 and June 2024; AbbVie's February 2024 list-price disclosure for Botox Cosmetic; the ASPS average fee tables for 2022 and 2023 and the method statements in its 2022 and 2023 statistics reports, all through Internet Archive copies; Guidepoint Qsight's December 2025 neurotoxin report, its May 2026 conference presentation, and an October 2026 press release; the Bureau of Labor Statistics consumer price index releases for February and May 2026 and its medical care fact sheet; ASPS's 2024 procedure counts as carried by a Cosmetic Injectables blog post; two peer-reviewed studies from 2023 and 2026, read as PubMed abstracts; three Zenoti pages from 2026; and a 2023 Federal Reserve Bank of Richmond brief. Percentage changes in ASPS fees and Zenoti tickets are worked out from the published data points, and each one shows its inputs.

RealSelf averages are patients' own reports, and the number of reviews behind them fell from 18,233 to 7,827. Qsight and Zenoti data are proprietary, and neither publishes a sample size. Zenoti sells practice software, and its data points come from its own customers. AbbVie's list price may differ from what a practice pays. The ASPS fee survey changed its sample between 2022 and 2023, and the 2024 counts reach us through a blog post. The Richmond result comes from grocery shoppers. Both journal studies cover cosmetic surgery, and the 2026 one measures stated willingness to pay; one of its authors discloses consulting ties to neurotoxin and filler makers. The practice-level reasoning in sections 4 and 5 is ours.

Fractional Aesthetics is a growth strategy practice for aesthetic medical businesses.